Title: Mastering ABGC Exam Domain 5: Healthcare
Systems & Professional Practice - Practice Test Bank with
Detailed Rationales
Subdomain 5a: Financial/Reimbursement Issues
Question 1:
A genetic counselor is requesting prior authorization for exome
sequencing for a 10-year-old patient with global developmental delay
and suspected genetic etiology. The patient's insurance is a commercial
payer. When drafting the medical necessity letter, which of the
following resources would be MOST helpful to ensure alignment with
current best practices for advocating for coverage?
a) The National Society of Genetic Counselors (NSGC) Code of Ethics
b) The American College of Medical Genetics and Genomics (ACMG)
Insurance Coverage Advocacy Toolkit c) Medicare's "Coverage with
Evidence Development" (CED) guidelines d) The patient's insurance
company's formulary for genetic testing
Rationale:
Correct Answer: b) The American College of Medical Genetics
and Genomics (ACMG) Insurance Coverage Advocacy Toolkit
o Rationale: The question directly asks about resources for
advocating for coverage, and the provided text specifically
mentions the "ACMG’s Insurance Coverage Advocacy
Toolkit" as relevant to financial/reimbursement issues and
prior authorization. This toolkit is designed to provide
practical guidance and resources for genetic professionals
navigating insurance coverage challenges.
, Incorrect Answer a) The National Society of Genetic
Counselors (NSGC) Code of Ethics
o Rationale: While the NSGC Code of Ethics is crucial for
professional practice, it focuses on ethical principles and
responsibilities, not specifically on the practicalities of
insurance reimbursement and advocacy tools. It's not the
most helpful resource for drafting a medical necessity letter
focused on coverage.
Incorrect Answer c) Medicare's "Coverage with Evidence
Development" (CED) guidelines
o Rationale: Medicare CED guidelines are payer-specific and
relevant to Medicare patients. The question specifies a
commercial payer. While understanding payer-specific
criteria is important, CED guidelines are not the most broadly
applicable resource for initial advocacy across different
payers. They are also more specific to Medicare, not
commercial insurance.
Incorrect Answer d) The patient's insurance company's
formulary for genetic testing
o Rationale: A formulary lists covered medications and
sometimes tests, but it doesn't provide guidance on
advocating for coverage or drafting medical necessity letters.
It tells you what is generally covered, not how to get
coverage for something that might require justification.
Question 2:
A genetic counselor is reviewing a denial of prior authorization for
chromosomal microarray analysis (CMA) for a patient with unexplained
intellectual disability. The denial cites "lack of medical necessity" based
on the payer's criteria, which prioritize single gene testing first.
,According to best practices and considering the need for efficient and
cost-effective diagnosis, what is the MOST appropriate next step?
a) Appeal the denial, emphasizing the established diagnostic yield of
CMA for intellectual disability according to ACMG guidelines. b) Order
targeted single-gene testing for the most common genes associated with
intellectual disability based on the payer's preference. c) Initiate a peer-
to-peer review with the payer's medical director to discuss the clinical
rationale for CMA. d) Advise the patient to switch to a different
insurance plan that is known to cover CMA more readily.
Rationale:
Correct Answer: a) Appeal the denial, emphasizing the
established diagnostic yield of CMA for intellectual disability
according to ACMG guidelines.
o Rationale: Appealing is a standard next step in denial
situations. Emphasizing ACMG guidelines is key as these are
recognized professional standards that support the medical
necessity of CMA in this context. This directly addresses the
payer's "lack of medical necessity" claim with evidence-
based support.
Incorrect Answer b) Order targeted single-gene testing for the
most common genes associated with intellectual disability
based on the payer's preference.
o Rationale: While payers have preferences, starting with
single-gene testing after considering CMA as a more
comprehensive first-tier test is often less efficient and
potentially more costly in the long run. CMA is often a more
appropriate initial test for unexplained ID based on
diagnostic yield and efficiency. Yielding to payer preference
without appeal may not be in the patient's best diagnostic
interest.
, Incorrect Answer c) Initiate a peer-to-peer review with the
payer's medical director to discuss the clinical rationale for
CMA.
o Rationale: Peer-to-peer review can be a useful step,
especially if the denial seems based on misunderstanding.
However, appealing first, with strong written justification
citing ACMG guidelines, is often a more direct and impactful
first step in the formal process. Peer-to-peer can follow if the
appeal is unsuccessful.
Incorrect Answer d) Advise the patient to switch to a different
insurance plan that is known to cover CMA more readily.
o Rationale: This is ethically problematic and impractical.
Insurance changes are complex and should not be advised
based solely on coverage of a single test. The genetic
counselor's role is to advocate within the existing system
first.
Subdomain 5b: Legal/Ethical Requirements
Question 3:
In a telehealth genetic counseling session, a patient requests that their
genetic test results be shared with their spouse, who is not present during
the session. To ensure HIPAA compliance and adhere to best practices
in data sharing, what is the MOST appropriate course of action for the
genetic counselor?
a) Share the results with the spouse via email, assuming spousal consent
is implied. b) Verbally share the results with the spouse during a follow-
up phone call, documenting the patient's initial request. c) Obtain
explicit, HIPAA-compliant authorization from the patient to share the
results with their spouse, outlining the specific information to be shared
and the method of sharing. d) Explain to the patient that genetic
Systems & Professional Practice - Practice Test Bank with
Detailed Rationales
Subdomain 5a: Financial/Reimbursement Issues
Question 1:
A genetic counselor is requesting prior authorization for exome
sequencing for a 10-year-old patient with global developmental delay
and suspected genetic etiology. The patient's insurance is a commercial
payer. When drafting the medical necessity letter, which of the
following resources would be MOST helpful to ensure alignment with
current best practices for advocating for coverage?
a) The National Society of Genetic Counselors (NSGC) Code of Ethics
b) The American College of Medical Genetics and Genomics (ACMG)
Insurance Coverage Advocacy Toolkit c) Medicare's "Coverage with
Evidence Development" (CED) guidelines d) The patient's insurance
company's formulary for genetic testing
Rationale:
Correct Answer: b) The American College of Medical Genetics
and Genomics (ACMG) Insurance Coverage Advocacy Toolkit
o Rationale: The question directly asks about resources for
advocating for coverage, and the provided text specifically
mentions the "ACMG’s Insurance Coverage Advocacy
Toolkit" as relevant to financial/reimbursement issues and
prior authorization. This toolkit is designed to provide
practical guidance and resources for genetic professionals
navigating insurance coverage challenges.
, Incorrect Answer a) The National Society of Genetic
Counselors (NSGC) Code of Ethics
o Rationale: While the NSGC Code of Ethics is crucial for
professional practice, it focuses on ethical principles and
responsibilities, not specifically on the practicalities of
insurance reimbursement and advocacy tools. It's not the
most helpful resource for drafting a medical necessity letter
focused on coverage.
Incorrect Answer c) Medicare's "Coverage with Evidence
Development" (CED) guidelines
o Rationale: Medicare CED guidelines are payer-specific and
relevant to Medicare patients. The question specifies a
commercial payer. While understanding payer-specific
criteria is important, CED guidelines are not the most broadly
applicable resource for initial advocacy across different
payers. They are also more specific to Medicare, not
commercial insurance.
Incorrect Answer d) The patient's insurance company's
formulary for genetic testing
o Rationale: A formulary lists covered medications and
sometimes tests, but it doesn't provide guidance on
advocating for coverage or drafting medical necessity letters.
It tells you what is generally covered, not how to get
coverage for something that might require justification.
Question 2:
A genetic counselor is reviewing a denial of prior authorization for
chromosomal microarray analysis (CMA) for a patient with unexplained
intellectual disability. The denial cites "lack of medical necessity" based
on the payer's criteria, which prioritize single gene testing first.
,According to best practices and considering the need for efficient and
cost-effective diagnosis, what is the MOST appropriate next step?
a) Appeal the denial, emphasizing the established diagnostic yield of
CMA for intellectual disability according to ACMG guidelines. b) Order
targeted single-gene testing for the most common genes associated with
intellectual disability based on the payer's preference. c) Initiate a peer-
to-peer review with the payer's medical director to discuss the clinical
rationale for CMA. d) Advise the patient to switch to a different
insurance plan that is known to cover CMA more readily.
Rationale:
Correct Answer: a) Appeal the denial, emphasizing the
established diagnostic yield of CMA for intellectual disability
according to ACMG guidelines.
o Rationale: Appealing is a standard next step in denial
situations. Emphasizing ACMG guidelines is key as these are
recognized professional standards that support the medical
necessity of CMA in this context. This directly addresses the
payer's "lack of medical necessity" claim with evidence-
based support.
Incorrect Answer b) Order targeted single-gene testing for the
most common genes associated with intellectual disability
based on the payer's preference.
o Rationale: While payers have preferences, starting with
single-gene testing after considering CMA as a more
comprehensive first-tier test is often less efficient and
potentially more costly in the long run. CMA is often a more
appropriate initial test for unexplained ID based on
diagnostic yield and efficiency. Yielding to payer preference
without appeal may not be in the patient's best diagnostic
interest.
, Incorrect Answer c) Initiate a peer-to-peer review with the
payer's medical director to discuss the clinical rationale for
CMA.
o Rationale: Peer-to-peer review can be a useful step,
especially if the denial seems based on misunderstanding.
However, appealing first, with strong written justification
citing ACMG guidelines, is often a more direct and impactful
first step in the formal process. Peer-to-peer can follow if the
appeal is unsuccessful.
Incorrect Answer d) Advise the patient to switch to a different
insurance plan that is known to cover CMA more readily.
o Rationale: This is ethically problematic and impractical.
Insurance changes are complex and should not be advised
based solely on coverage of a single test. The genetic
counselor's role is to advocate within the existing system
first.
Subdomain 5b: Legal/Ethical Requirements
Question 3:
In a telehealth genetic counseling session, a patient requests that their
genetic test results be shared with their spouse, who is not present during
the session. To ensure HIPAA compliance and adhere to best practices
in data sharing, what is the MOST appropriate course of action for the
genetic counselor?
a) Share the results with the spouse via email, assuming spousal consent
is implied. b) Verbally share the results with the spouse during a follow-
up phone call, documenting the patient's initial request. c) Obtain
explicit, HIPAA-compliant authorization from the patient to share the
results with their spouse, outlining the specific information to be shared
and the method of sharing. d) Explain to the patient that genetic
